South Korea · Research startup
South Korea · Cyrus Therapeutics
Cyrus Therapeutics is a biotechnology company based in Seoul, founded in 2019.
Funding reportedLast round: Series B
About Cyrus Therapeutics
Cyrus Therapeutics is a biotechnology company based in Seoul, founded in 2019.
The company focuses on discovering and developing small molecule medicines aimed at targeting "undruggable" proteins associated with cancer and chronic diseases that have significant unmet needs. With a team of 11-20 employees, Cyrus operates under the NAICS code 541714, specializing in biotechnology research. Cyrus has made notable advancements, including receiving IND approvals from the South Korean MFDS and the U.S. FDA for its product CYRS1542, an oral GSPT1 molecular glue degrader targeting neuroendocrine cancer. The company emphasizes innovative approaches, developing small molecule inhibitors, targeted protein degraders, and immuno-oncology agents. Its mission is to address challenging therapeutic targets in oncogenic pathways, aiming to improve treatment options for patients with chronic or life-threatening diseases.
What company datasets say Cyrus Therapeutics raised
Funding, as reported
The company, in detail
What they build
Known for
biotechnology research
Built with from their website
NAVERApacheViewport MetaMicrosoft ExchangeMicrosoft 365 Apps & ServicesMobile FriendlyMicrosoft Exchange OnlineMicrosoft 365Apache HTTP ServerOutlook
+2 more
Microsoft Email ProvidersGoogle Search Console
- Sector
- Research
- Industry code
- NAICS 541714, SIC 8731
- Region
- Seoul
- Full record
- Every detail in the company directory
Research in South Korea
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Cyrus Therapeutics in front of investors. Or tell us what we have wrong.